ANDA 208741, held by Lupin. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 208741 (Doxycycline Hyclate), held by Lupin, was first approved by FDA on Aug 11, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 11, 2023 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 50MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 60MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 75MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 80MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 100MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 120MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 150MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 200MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters